Top 20 BioPharma Companies based on 2019 Total Revenue

The global biopharma companies are developing novel therapies & devices which is- in turn- enhancing their portfolio and encouraging them in this undergoing competition to stay in the topmost position The top 20 companies chartbusters changed their 2019 ranking- but the history of Johnson and Johnson did not change and it continued being at the…

ByPrince GiriApril 24, 2020

INSIGHTS+

Insights+: COVID-19 Healthcare News Monthly Updates – August 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019 PharmaShots is keeping a track of all of the important updates in the Life-sciences sector, where…

BySenior EditorApril 9, 2020

INSIGHTS+

Insights+: Breakthrough Therapy Designation by the US FDA in 2019

Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012. The Breakthrough Designation is granted to the drug candidates as monotherapy or in combination with other drugs intended to treat serious or life-threatening diseases and has shown substantial improvement over available…

BySenior EditorMarch 13, 2020

INSIGHTS+

Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020

The 2020 JP Morgan Healthcare Conference was loaded with insights from key pharma companies. An analysis of events and catalysts that were announced or updated at the conference these days are included. Our PharmaShots team summarized the key deals which were presented during the updates from companies from Jan 13 to Jan 16, 2020. Date…

BySenior EditorFebruary 7, 2020

INSIGHTS+

PharmaShots’ Key Highlights of Fourth Quarter 2019

1. Pfizer Launched its Zirabev (biosimilar, bevacizumab) in the US by the year end 2019 Date - Oct 01, 2019 Product - Zirabev (biosimilar, bevacizumab) The biosimilar was launched in the US on Dec 31, 2019 following the settlement between Genentech and Pfizer granting all global rights of the product to the Pfizer. In Sept 2019,…

BySenior EditorJanuary 24, 2020

INSIGHTS+

PharmaShots’ Most Read News of 2019

The year 2019 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements and gaining approvals. Our team has compiled a list of 20 most read life sciences news on PharmaShots in 2019. 1. Celltrion Signed an Exclusive Co-Marketing Agreement with Juno in Australia Juno provided sales promotion…

BySenior EditorJanuary 10, 2020

INSIGHTS+

Insights+: The US FDA New Drug Approvals in November 2019

The US FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 35 new products so far in 2019. In 2018 FDA approved 59 novel products including 42 New Chemical Entities and 17 Biologics while breaking its last year's record of approvals. However, there is a significant…

BySenior EditorDecember 13, 2019

INSIGHTS+

Insights+: The US FDA New Drug Approvals in September and October 2019

The US FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 35 new products so far in 2019. In 2018 FDA approved 59 novel products including 42 New Chemical Entities and 17 Biologics while breaking its last year's record of approvals. However, there is a significant…

BySenior EditorNovember 15, 2019

TOP 20

Top 20 Life Sciences Deals of 2018 Based on Total Deal Value

Healthcare- pharmaceutical- and biotech companies are gearing up to tap new markets as they look to consolidate their positions after a spate of mergers & acquisitions and licensing partnerships in 2018. The highest valued deal proved to be of Takeda's acquisition of Shire for $57B with the focus on global R&D- its robust and modality-diverse…

ByPrince GiriAugust 23, 2019

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2019

The first quarter of 2019 has marked with major events in the pharma & biotech industries. We have gathered the key highlights of the quarter, which was starting with the blockbuster news, where Celgene had acquired BMS for $74B. Moving to the next news, acquisition of Loxo Oncology for $8B, in addition to Spark Therapeutics…

BySenior EditorAugust 4, 2019

Top 20 BioPharma Companies based on 2019 Total Revenue

Insights+: COVID-19 Healthcare News Monthly Updates – August 2020

Insights+: Breakthrough Therapy Designation by the US FDA in 2019

Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020

PharmaShots’ Key Highlights of Fourth Quarter 2019

PharmaShots’ Most Read News of 2019

Insights+: The US FDA New Drug Approvals in November 2019

Insights+: The US FDA New Drug Approvals in September and October 2019

Top 20 Life Sciences Deals of 2018 Based on Total Deal Value

PharmaShots’ Key Highlights of First Quarter 2019

Contact US

FOLLOW US